BLACKSBURG, Va. In the Blue Ridge Mountains of Virginia, a groundbreaking initiative is underway that could reshape the future of organ transplantation. This unique research farm is home to some of the world’s cleanest pigs, bred and raised specifically to produce organs for human transplantation.

The farm, operated by Revivicor Inc., represents a leap forward in xenotransplantation, where gene-edited pig organs are being prepared for potential human use. Visitors to this high-security facility are met with stringent biosecurity measures: vehicle decontamination, changing into medical scrubs, and disinfecting boots before entering the climate-controlled barns.

“These are precious animals,” said David Ayares, Chief Scientific Officer at Revivicor, who has dedicated decades to perfecting the genetic modifications required for successful organ transplantation. His efforts have led to the first successful gene-edited pig organ transplants into humans.

Just a few miles away in Christiansburg, Virginia, a new, even more advanced facility is being prepared. This state-of-the-art building, more akin to a pharmaceutical plant than a traditional farm, will house a herd of pigs specifically bred to supply organs for future clinical trials. The facility features extreme biosecurity measures, with access restricted to select employees who undergo thorough decontamination processes before entering.

Matthew VonEsch of United Therapeutics, Revivicor’s parent company, explained, “We designed this facility to protect the pigs against contamination from the environment and from people. Every person that enters this building is a possible pathogen risk.”

The demand for organ transplants is overwhelming, with thousands of Americans dying each year due to organ shortages. Scientists hope that using genetically engineered pigs could provide a viable solution. Pigs are being engineered to possess human-like organ traits, aiming to alleviate the chronic shortage of human donors.

In the U.S., there have been four experimental transplants involving pig organs, including two hearts and two kidneys. Although these procedures were performed on critically ill patients who ultimately did not survive, they provided crucial data for ongoing research. The FDA is now reviewing these results and awaiting further studies before making regulatory decisions.

The process of creating these bioengineered pigs involves modifying their genes to minimize the risk of organ rejection and other complications. Initially, Revivicor removed a gene that produces a sugar molecule triggering immediate immune response in humans. Subsequent modifications have involved additional gene edits to further reduce immune reactions and optimize organ function.

The cloning of these genetically modified pigs is performed with meticulous precision, similar to the process used to create Dolly the sheep. Scientists inject modified DNA into pig eggs, which are then implanted into surrogate sows to develop into piglets.

On the research farm, these pigs live in luxury, with their accommodations designed to ensure maximum cleanliness and comfort. Music is played to acclimate piglets to human voices, and the environment is meticulously controlled to maintain high standards of hygiene.

“There are certain ones I say hi to,” noted Suyapa Ball, Revivicor’s head of porcine technology and farm operations. “You have to give them a good life. They’re giving their lives for us.”

United Therapeutics’ new facility in Christiansburg aims to produce up to 125 pig organs annually, with the potential for even larger facilities in the future. The company envisions scaling up to produce up to 2,000 organs per year across multiple locations.

As research progresses, the field of xenotransplantation remains cautiously optimistic. “The next two or three years are going to be super exciting,” Ayares said. The hope is that these advancements will eventually lead to a new era of organ transplantation, addressing the critical shortage of human donors and saving countless lives.